Prostate Irreversible Electroporation for Localized Prostate Cancer
Official title: Evaluation of the Effectiveness of Irreversible Electroporation for the Treatment of Prostate Cancer
Run by Chinese University of Hong Kong · NCT06886321 · Data updated 2026-11-12
A minimally invasive treatment using irreversible electroporation is tested to see if it can treat localized prostate cancer while preserving urinary and sexual function.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 85 Years |
| Sex | Men only |
| Enrollment | 10 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | June 30, 2025 |
| Main results expected | January 31, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT06886321 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 40–85 with localized prostate cancer, a visible index lesion on MRI, and biopsy-confirmed disease <=T2, Gleason <=7, or PSA <= 20 ng/mL.
✕Probably not a fit
Patients with contraindications to MRI contrast, active urinary infections, significant bladder pathology, urethral stricture, neurogenic bladder or sphincter issues, or inability to provide informed consent may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the safety and effectiveness of irreversible electroporation (IRE) as a focal therapy for localized prostate cancer. Eligible men with visible MRI-detected lesions and favorable biopsy features may receive IRE to target only the tumor-bearing area. The approach aims to reduce treatment-related morbidity compared with traditional options like surgery or radiotherapy, while maintaining cancer control. The study is conducted at Prince of Wales Hospital, Hong Kong, led by the Chinese University of Hong Kong. Outcomes include safety and preliminary effectiveness in appropriately selected patients.
Why it matters
Potential benefit: If successful, patients may experience cancer control with fewer urinary and sexual side effects compared with more invasive treatments.
How similar studies have gone: Prior focal therapies using similar principles have shown potential in balancing cancer control with functional preservation, though IRB approval and broader evidence vary by modality.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men aged between 40 - 85 years * Visible index lesion(s) on MRI * Found to have localized prostate cancer after MRI-USG fusion targeted biopsy or USG-guided template biopsy: Clinical tumour stage \<=T2, or Gleason score \<=7, or PSA \<= 20 ng/ml Exclusion Criteria: * Patients unfit for contrast MRI exam * Patients with active urinary tract infection * Patients with bladder pathology including bladder stone and bladder cancer * Patients with urethral stricture * Patients with neurogenic bladder and/or sphincter abnormalities * Patients who fail to give informed consent
Where it's running
-
Prince of Wales Hospital, the Chinese University of Hong Kong
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Chi Hang Yee, MBBS — Chinese University of Hong Kong
- Study coordinator: Chi Hang Yee, MBBS
- Email: yeechihang@surgery.cuhk.edu.hk
- Phone: +852 35053933
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.